Barbara Stopschinski

Dr. Barbara Stopschinski

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2023 in eLife
Verified
Journal Article
Open access
VPValerie Ann Perez
Valerie Ann Perez
DSDavid W Sanders
David W Sanders
AMAyde Mendoza-Oliva
Ayde Mendoza-Oliva
BSBarbara Stopschinski
Barbara Stopschinski
VMVishruth Mullapudi
Vishruth Mullapudi
MDMarc I Diamond
Marc I Diamond
Neurodegenerative tauopathies are caused by accumulation of toxic tau protein assemblies. This appears to involve template-based seeding events, whereby tau monomer changes conformation and is recruited to a growing aggregate. Several large families of chaperone proteins, including Hsp70s and J domain proteins (JDPs), cooperate to regulate the folding of intracellular proteins such as tau, but the factors that coordinate this activity are not well known. The JDP DnaJC7 binds tau and reduces its intracellular aggregation. However, it is unknown whether this is specific to DnaJC7 or if other JDPs might be similarly involved. We used proteomics within a cell model to determine that DnaJC7 co-purified with insoluble tau and colocalized with intracellular aggregates. We individually knocked out every possible JDP and tested the effect on intracellular aggregation and seeding. DnaJC7 knockout decreased aggregate clearance and increased intracellular tau seeding. This depended on the ability of the J domain (JD) of DnaJC7 to stimulate Hsp70 ATPase activity, as JD mutations that block this interaction abrogated the protective activity. Disease-associated mutations in the JD and substrate binding site of DnaJC7 also abolished its protective activity. DnaJC7 thus specifically regulates tau aggregation in cooperation with Hsp70.

1 January 2023 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
BSBarbara Stopschinski
Barbara Stopschinski
RWRick A. Weideman
Rick A. Weideman
DMDanni McMahan
Danni McMahan
DJDavid A. Jacob
David A. Jacob
BLBertis B. Little
Bertis B. Little
OSOlaf Stuve
Olaf Stuve
Alzheimer’s disease (AD) is an untreatable cause of dementia, and new therapeutic approaches are urgently needed. AD pathology is defined by extracellular amyloid plaques and intracellular neurofibrillary tangles. Research of the past decades has suggested that neuroinflammation plays a critical role in the pathophysiology of AD. This has led to the idea that anti-inflammatory treatments might be beneficial. Early studies investigated non-steroidal anti-inflammatory drugs (NSAIDS) such as indomethacin, celecoxib, ibuprofen, and naproxen, which had no benefit. More recently, protective effects of diclofenac and NSAIDs in the fenamate group have been reported. Diclofenac decreased the frequency of AD significantly compared to other NSAIDs in a large retrospective cohort study. Diclofenac and fenamates share similar chemical structures, and evidence from cell and mouse models suggests that they inhibit the release of pro-inflammatory mediators from microglia with leads to the reduction of AD pathology. Here, we review the potential role of diclofenac and NSAIDs in the fenamate group for targeting AD pathology with a focus on its potential effects on microglia.

5 June 2022 in Geriatrics
Verified
Journal Article
Open access
PDF file
HCHsueh-Sheng CHIANG
Hsueh-Sheng CHIANG
AKAlka Khera
Alka Khera
BSBarbara Stopschinski
Barbara Stopschinski
OSOlaf Stuve
Olaf Stuve
JHJohn Hart
John Hart
TNTrung Phuoc Nguyen
Trung Phuoc Nguyen
Several important questions regarding cognitive aging and dementia in older people with multiple sclerosis (PwMS) are the focus of this narrative review: Do older PwMS have worse cognitive decline compared to older people without MS? Can older PwMS develop dementia or other neurodegenerative diseases such as Alzheimer’s disease (AD) that may be accelerated due to MS? Are there any potential biomarkers that can help to determine the etiology of cognitive decline in older PwMS? What are the neural and cellular bases of cognitive aging and neurodegeneration in MS? Current evidence suggests that cognitive impairment in MS is distinguishable from that due to other neurodegenerative diseases, although older PwMS may present with accelerated cognitive decline. While dementia is prevalent in PwMS, there is currently no consensus on defining it. Cerebrospinal fluid and imaging biomarkers have the potential to identify disease processes linked to MS and other comorbidities—such as AD and vascular disease—in older PwMS, although more research is required. In conclusion, one should be aware that multiple underlying pathologies can coexist in older PwMS and cause cognitive decline. Future basic and clinical research will need to consider these complex factors to better understand the underlying pathophysiology, and to improve diagnostic accuracy.

Verified
Journal Article
Open access
PDF file
NKNaghmeh Abbasi Kasbi
Naghmeh Abbasi Kasbi
BSBarbara Stopschinski
Barbara Stopschinski
APAlanna Gabrielle Polyak
Alanna Gabrielle Polyak
AMAgastya Reddy Malladi
Agastya Reddy Malladi
NMNavid Manouchehri
Navid Manouchehri
OSOlaf Stuve
Olaf Stuve
The neuroendocrine and immune systems interact bidirectionally through shared ligands and receptors during inflammation, thereby regulating immune responses. Leptin, primarily known for its role in energy metabolism and appetite regulation, also modulates neuroinflammatory pathways. Its receptors are widely expressed on immune cells and contribute to immune mechanisms implicated in the pathogenesis of neuroinflammatory disorders such as multiple sclerosis (MS) and Alzheimer’s disease (AD). This review highlights recent advances in understanding leptin’s role in immune regulation, with a focus on its impact on MS and AD. A comprehensive literature review was conducted until October 2025, using PubMed, Google Scholar, and Scopus to identify studies investigating leptin in neuroinflammatory conditions, particularly MS and AD. Leptin exerts broad immunomodulatory effects by activating T cells, dendritic cells, and microglia, and promoting their proliferation and phagocytosis. Its elevation enhances Th1 and Th17 responses, drives pro-inflammatory macrophage phenotype polarization, and suppresses regulatory T cell and Th2 responses, immune pathways involved in MS. Peripheral leptin levels are increased in MS, especially during disease exacerbations. In contrast, in AD, they are typically reduced, particularly in patients with normal body mass index (BMI), where their decline contributes to amyloid-β and tau pathology. These divergent patterns position leptin as a bidirectional regulator at the intersection of immunity and neurodegeneration. Additionally, its protective or detrimental effects likely depend on whether it acts under physiological conditions or in the context of obesity-induced leptin resistance. Elevated leptin levels in obesity exacerbate inflammation and diminish its neuroprotective effects. In conclusion, leptin is elevated in MS patients but downregulated in AD, reflecting its bidirectional effects. In leptin resistance, peripheral proinflammatory signaling is maintained while central leptin signaling is restricted, thereby potentially promoting autoimmunity in MS and limiting neuroprotection in AD. Further mechanistic and longitudinal studies are needed to clarify the relationship between leptin dysregulation, leptin resistance, neuroinflammatory and neurodegenerative diseases.

24 January 2025 in Current Treatment Options in Neurology
Verified
Journal Article
Open access
PDF file
CHCarolin Hoehne
Carolin Hoehne
OSOlaf Stuve
Olaf Stuve
BSBarbara Stopschinski
Barbara Stopschinski
Purpose of Review Multiple Sclerosis (MS) is a chronic inflammatory neurological disorder affecting over 2.8 million people worldwide. It is characterized by distinct phenotypes, such as relapsing-remitting MS (RRMS) and progressive forms (SPMS, PPMS). While disease-modifying therapies (DMTs) effectively target inflammation and reduce relapse rates in RRMS, they are less effective in progressive MS, where neurodegeneration becomes more prominent. This review explores the emerging role of the microtubule-associated protein tau, typically associated with neurodegenerative diseases like Alzheimer’s disease, in MS pathology and its potential as a therapeutic target. Recent Findings Tau is primarily involved in stabilizing neuronal microtubules. Under pathological conditions, tau alters and aggregates into neurofibrillary tangles, contributing to neuronal dysfunction and degeneration. Recent studies have identified tau seeds and pathological tau in MS, particularly in and adjacent to lesions in human brain tissue and rodent models of MS. Evidence suggests a bidirectional relationship between tau pathology and inflammation, where tau drives inflammatory responses, and inflammation exacerbates tau aggregation. However, understanding the role of tau in MS remains limited, particularly in progressive forms where neurodegeneration is most severe. Summary The involvement of tau in MS represents a promising avenue for research and therapeutic intervention, particularly in progressive forms of the disease. Addressing gaps in knowledge, such as developing better MS models, investigating tau aggregation in MS, and identifying reliable biomarkers, could pave the way for novel tau-targeted therapies. Such approaches hold the potential to mitigate neurodegeneration and improve outcomes for patients with progressive MS.

16 March 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
VPValerie A. Perez
Valerie A. Perez
DSDavid W. Sanders
David W. Sanders
AMAyde Mendoza-Oliva
Ayde Mendoza-Oliva
BSBarbara Stopschinski
Barbara Stopschinski
VMVishruth Mullapudi
Vishruth Mullapudi
MDMarc I. Diamond
Marc I. Diamond
Neurodegenerative tauopathies are caused by accumulation of toxic tau protein assemblies. This appears to involve template-based seeding events, whereby tau monomer changes conformation and is recruited to a growing aggregate. Several large families of chaperone proteins, including Hsp70s and J domain proteins (JDPs) cooperate to regulate the folding of intracellular proteins such as tau, but the factors that coordinate this activity are not well known. The JDP DnaJC7 binds tau and reduces its intracellular aggregation. However, it is unknown whether this is specific to DnaJC7 or if other JDPs might be similarly involved. We used proteomics within a cell model to determine that DnaJC7 co-purified with insoluble tau and colocalized with intracellular aggregates. We individually knocked out every possible JDP and tested the effect on intracellular aggregation and seeding. DnaJC7 knockout decreased aggregate clearance and increased intracellular tau seeding. This depended on the ability of the J domain (JD) of DnaJC7 to bind to Hsp70, as JD mutations that block binding to Hsp70 abrogated the protective activity. Disease-associated mutations in the JD and substrate binding site of DnaJC7 also abrogated its protective activity. DnaJC7 thus specifically regulates tau aggregation in cooperation with Hsp70.